Topical immunomodulators (TIMs) include both immunostimulatory and immunosuppressive
agents. Newer immunostimulatory compounds such as imidazoquinolines (eg imiquimod) …

Background Despite numerous therapeutic options the treatment of common warts and
molluscum contagiosum remains unsatisfactory for both patients and physicians. Imiquimod …

Background: Genital warts are a common sexually transmitted disease caused by human
papillomavirus. Imiquimod is a novel immune-response modifier capable of inducing a …

Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream
for application by the patient. It is the first agent of its class, the immune response modifiers …

Topical imiquimod 5% cream (Aldara™) is an immune response modulator that is indicated
for the treatment of external anogenital warts, superficial basal cell carcinoma and actinic …

External genital and anal warts (acuminate condyloma) were the first medical indication the
topical immune response modifier imiquimod was approved for in 1997. Since then, many …

Imiquimod is a topical immune-response modifier with antitumour and antiviral properties.
These actions of imiquimod are dependent on focal activation of the immune system and the …

Background Viral warts may cause significant morbidity in individuals unable to mount an
adequate T‐helper 1 cell‐mediated immune response to human papillomavirus. Imiquimod …

Genital human papillomavirus infection is one of the most common sexually transmitted
diseases. Imiquimod is a new agent, an immune-response modifier, that has been …

The prevalence of human papillomavirus (HPV) infection is continuing to increase globally,
with approximately five million new cases in the USA per year. Many different subtypes of …